Doubling prostate cancer drug dose shows promise when standard treatment fails

This study tested whether doubling the dose of the prostate cancer drug abiraterone acetate could help control the disease in patients whose cancer was progressing despite standard treatment. Researchers enrolled 94 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. They first gave the standard dose and measured drug levels in the blood, then doubled the dose for patients whose cancer progressed within 6 months and had low drug levels.